|
LYRM2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62436730732907E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
<1E-12 |
| Normal-vs-Stage2 |
7.41549999960789E-07 |
| Normal-vs-Stage3 |
<1E-12 |
| Normal-vs-Stage4 |
<1E-12 |
| Stage1-vs-Stage2 |
3.939900E-02 |
| Stage1-vs-Stage3 |
1.082000E-01 |
| Stage1-vs-Stage4 |
1.142840E-03 |
| Stage2-vs-Stage3 |
3.437600E-03 |
| Stage2-vs-Stage4 |
6.2084999999934E-05 |
| Stage3-vs-Stage4 |
1.173010E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.11022302462516E-16 |
| Normal-vs-AfricanAmerican |
7.55209999980799E-07 |
| Normal-vs-Asian |
6.23934237609092E-12 |
| Caucasian-vs-AfricanAmerican |
3.257400E-01 |
| Caucasian-vs-Asian |
6.373400E-01 |
| AfricanAmerican-vs-Asian |
5.471600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
<1E-12 |
| Normal-vs-Female |
1.62447832963153E-12 |
| Male-vs-Female |
6.230400E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62481139653892E-12 |
| Normal-vs-Age(41-60Yrs) |
1.11022302462516E-16 |
| Normal-vs-Age(61-80Yrs) |
6.00408611717285E-13 |
| Normal-vs-Age(81-100Yrs) |
1.55906999999011E-05 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
8.992200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
8.745000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.136400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.777400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
2.404400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
1.363160E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.009230E-04 |
| Classical-VS-Follicular |
2.156700E-04 |
| Classical-VS-Other |
6.162200E-01 |
| Classical-VS-Normal |
1.71529457304587E-13 |
| Tall-VS-Follicular |
6.1118999861165E-09 |
| Tall-VS-Other |
2.020200E-01 |
| Tall-VS-Normal |
<1E-12 |
| Follicular-VS-Other |
1.221620E-01 |
| Follicular-VS-Normal |
3.66409999996709E-06 |
| Other-VS-Normal |
2.595800E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
4.37427871702312E-14 |
| Normal-vs-N1 |
2.22044604925031E-16 |
| N0-vs-N1 |
7.213600E-04 |
|
|
